atai Impact, the philanthropic program of atai Life Sciences
(Nasdaq: ATAI) (“atai”) and the Multidisciplinary Association for
Psychedelic Studies (MAPS) today announced a $500,000 donation from
atai Impact to MAPS. This donation is an important demonstration of
the synergy and collaboration across the leading non-profit and
commercial organizations to advance psychedelic medicine and tackle
the escalating mental health crisis affecting over one billion
people worldwide.1
“We were already facing a global mental health crisis, but the
pandemic has escalated this even further. To solve this crisis
requires innovation, passion and collaboration,” said Florian
Brand, CEO and Co-Founder, atai Life Sciences. “MAPS has been the
driving force of the psychedelic renaissance over the last 35
years, promoting healing and well-being through education and
research into psychedelics and their potential to revolutionize
mental health for those in need. Their work has been an incredible
source of inspiration and motivation to all of us at atai, and
we’re pleased to work alongside them.”
“Mental health is a fundamental human right – one that today’s
healthcare systems are not equipped to provide for. The sheer scale
of the global mental health crisis calls for a large-scale response
from nonprofit, public benefit, and for-profit organizations
working together to meet the collective need. With this gift, atai
Impact is demonstrating their commitment to our shared values of
healing and health equity,” added Rick Doblin, Ph.D., Founder and
Executive Director, MAPS.
The $500,000 donation from atai Impact is for multi-year support
of MAPS’ ongoing initiatives, including its Health Equity Program.
The program aims to optimize access and healing through the
development of a diverse network of therapy providers reflecting
the diverse experiences of those who experience trauma and mental
health conditions.
“We launched atai Impact, our philanthropic arm, because we know
there must be a cross-sector approach to healing mental health
conditions for everyone, everywhere,” said Rae Richman, Vice
President of atai Impact. “It’s an incredibly exciting and pivotal
time for psychedelic medicine and atai Impact is committed to
ensuring that, as the field grows, it promotes equitable,
sustainable and effective practices.”
The donation from atai Impact to MAPS was issued through the
atai Impact Fund at Vanguard Charitable.
Live media briefing and Q&A
Florian Brand, CEO of atai Life Sciences, and Rick Doblin,
founder and executive director of MAPS will host an online press
briefing and live media Q&A at 11.00am ET on Wednesday,
February 16.
To pre-register and secure your attendance please visit:
https://us02web.zoom.us/webinar/register/WN_Ndd2dIznSKyFKe9D0RSnUw.
After registering, you will receive a confirmation email with
joining information for the call.
About atai Impact
atai Impact was launched by atai Life Sciences, in October 2021,
to harness the power of innovative mental health approaches for
positive social change.
The key pillars of atai Impact’s activities are: advancing
education, expanding access, and supporting the wider ecosystem of
mental health care. atai Impact has an initial focus on the
psychedelics sector, given its emerging potential in tackling the
growing mental health crisis.
The establishment of atai Impact is based on atai Life Sciences’
position that harmonization across commercial and non-profit
entities represents the best path forward to address all aspects of
the escalating global mental crisis.
About atai
atai is a clinical-stage biopharmaceutical company aiming to
transform the treatment of mental health disorders. atai was
founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape. atai
is dedicated to acquiring, incubating, and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. atai has
offices in New York, London, and Berlin. For more information,
please visit www.atai.life.
About
MAPS
Founded in 1986, MAPS is a 501(c)(3) non-profit research and
educational organization that develops medical, legal, and cultural
contexts for people to benefit from the careful uses of
psychedelics and marijuana. MAPS is sponsoring the most advanced
psychedelic therapy research in the world: Phase 3 clinical trials
of MDMA-assisted therapy for PTSD. Since its founding, MAPS has
raised over $130 million for psychedelic and marijuana research and
education and has earned both the Guidestar Platinum Seal of
Transparency and a 4-Star Rating from Charity Navigator.
References:
- Rehm J, Shield KD. Global Burden of
Disease and the Impact of Mental and Addictive Disorders. Curr
Psychiatry Rep. 2019;21(2):10.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release (including without limitation, the atai Impact program and
any other future philanthropic endeavors by atai) that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and uncertainties
that could cause actual results to differ materially from those
projected, including, without limitation, the important factors
discussed under the caption “Risk Factors” in atai's prospectus
pursuant to Rule 424(b) filed with the U.S. Securities and Exchange
Commission (“SEC”) on June 21, 2021, and in atai’s other filings
with the SEC. atai disclaims any obligation or undertaking to
update or revise any forward-looking statements contained in this
press release, other than to the extent required by applicable
law.
Contact Information
For atai Impact:Email: Impact@atai.life
Media Contact: Camilla Dormer VP,
Communications Email: camilla@atai.life
Investor Contact: Chad Messer VP, Investor
Relations Email: chad@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024